[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362459-105":3,"doc-detail-362459-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","analysis-of-the-efficacy-of-camrelizumabcetuximab-neoadjuvant-therapy-in-patients-with-loco-regionally-advanced-laryngeal-and-hypopharyngeal-cancer-and-the-prognostic-value-of-nlrsii","Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII","","Laryngeal and hypopharyngeal squamous cell carcinomas are common head and neck malignancies, requiring a balance between tumor control and preservation of laryngeal function. This retrospective study assessed whether different neoadjuvant regimens improve efficacy and laryngeal outcomes and evaluated prognostic biomarkers. Data from 110 patients with loco-regionally advanced disease were compared across three treatment groups using survival analyses, ROC testing, and multivariate Cox regression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/analysis-of-the-efficacy-of-camrelizumabcetuximab-neoadjuvant-therapy-in-patients-with-loco-regionally-advanced-laryngeal-and-hypopharyngeal-cancer-and-the-prognostic-value-of-nlrsii/362459/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/analysis-of-the-efficacy-of-camrelizumabcetuximab-neoadjuvant-therapy-in-patients-with-loco-regionally-advanced-laryngeal-and-hypopharyngeal-cancer-and-the-prognostic-value-of-nlrsii/362459.png","ImageObject",300,407,{"name":42,"@type":43},"Connor ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient population and study design were used to evaluate neoadjuvant therapy efficacy?","Question",{"text":63,"@type":64},"A retrospective study analyzed 110 patients with loco-regionally advanced laryngeal and hypopharyngeal cancer, comparing three neoadjuvant treatment regimens.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did camrelizumab plus TP chemotherapy perform compared with TP chemotherapy alone?",{"text":68,"@type":64},"Compared with TP alone, camrelizumab plus TP significantly improved endpoints including ORR, 2-year PFS, and 2-year LFS, while the 2-year OS did not show a significant improvement.",{"name":70,"@type":61,"acceptedAnswer":71},"Which biomarkers were identified as independent prognostic factors and how were they evaluated?",{"text":72,"@type":64},"SII, NLR, and N stage were independent prognostic factors in Cox regression analysis, and ROC curve analysis assessed their predictive performance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362459,1790286219,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"Cai etal. World Journal of Surgical Oncology (2026) 24:88  \n[https://doi.org/10.1186/s12957-026-04213-w](https://doi.org/10.1186/s12957-026-04213-w)  \nWorld Journal of Surgical Oncology  \nRESEARCH Open Access  \nAnalysis of the efficacy of camrelizumab/ cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII  \nNannan Cai1, Haotian Wei1, Yiyang Chen1, Jia Wang1, Penghui Li 1 and Chuncheng Hao 1*  \nAbstract  \nBackground Laryngeal and hypopharyngeal squamous cell carcinomas are among the most common head and neck malignancies, presenting a dual clinical challenge of achieving tumor eradication while preserving laryngeal function. This study evaluated the efficacy and preservation of laryngeal function effects of different neoadjuvant treatment regimens in patients.  \nMethods This retrospective study analyzed data from 110 patients with loco-regionally advanced laryngeal and hypopharyngeal cancer. Patients were categorized into three groups based on the neoadjuvant treatment regimens administered: TP chemotherapy group (albumin-bound paclitaxel plus cisplatin), camrelizumab plusTP chemotherapy group, and cetuximab plusTP chemotherapy group. To make a Kaplan-Meier survival curve plot for 3 groups and do a log-rank test on these groups. We executed receiver operation capability (ROC) curve examination and a multivariate Coxproportional dangers regression to recognize separate prognostic determinants for 2-year overall survival (OS) .  \nResults Compared with TP chemotherapy alone, camrelizumab plusTP chemotherapy demonstrated significant improvements in multiple endpoints (all P \u003C 0. 05) . The objective response rate (ORR) in the camrelizumab plus  \nTP chemotherapy group was 90 . 0%, the 2-year progression-free survival (PFS) rate was 75 . 0%, and the 2-year laryngectomy-free survival (LFS) rate was 67 . 5% . However, the 2-year OS rate was 80 . 0%, indicating no significant improvement (P >0. 05) . The cetuximab plusTP chemotherapy group did not demonstrate significant improvements in any of the above three endpoints (all P >0. 05) . No significant difference was observed in the incidence of  \nmajor adverse events among the three groups (P >0. 05) . Cox regression analysis revealed that the systemic immunoinflammatory index (SII), neutrophil-lymphocyte ratio (NLR), and N stage were independent prognostic  \n*Correspondence:  \nChuncheng Hao [HaoChuncheng1980@163.com](HaoChuncheng1980@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nCai et al. World Journal of Surgical Oncology (2026) 24:88 Page 2 of 11  \nfactors. ROC curve analysis demonstrated that the areas under the curve (AUC) for SII and NLR in predicting prognosis were 0.839 (95% confidence interval [CI]: 0 .755–0. 923) and 0.853 (95% ","cbCainDnrcDRT9nz","https://ap.wps.com/l/cbCainDnrcDRT9nz","pdf",1807686,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What patient population and study design were used to evaluate neoadjuvant therapy efficacy?\",\"answer\":\"A retrospective study analyzed 110 patients with loco-regionally advanced laryngeal and hypopharyngeal cancer, comparing three neoadjuvant treatment regimens.\"},{\"question\":\"How did camrelizumab plus TP chemotherapy perform compared with TP chemotherapy alone?\",\"answer\":\"Compared with TP alone, camrelizumab plus TP significantly improved endpoints including ORR, 2-year PFS, and 2-year LFS, while the 2-year OS did not show a significant improvement.\"},{\"question\":\"Which biomarkers were identified as independent prognostic factors and how were they evaluated?\",\"answer\":\"SII, NLR, and N stage were independent prognostic factors in Cox regression analysis, and ROC curve analysis assessed their predictive performance.\"}]","Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII | PDF",1790147823,28,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59fcf23d60ae9d58fa684f8a5b23c6a5.webp",983,1310,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a9d7e629fd68740a96863e22fcb65c3.webp",982,1309,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/274805d2ede90bbd5992ac99e4623568.webp",981,1308,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85d8f39a09f91d3cf2e983c3883d7263.webp",980,1306,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]